Biophytis SA logo
Biophytis SA BPTS

Annual report 2023
added 12-27-2025

report update icon

Biophytis SA EBITDA 2011-2026 | BPTS

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Biophytis SA

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - -26.8 M -13.9 M -15.7 M -13.9 M -9.7 M -7.77 M -3.12 M -659 K -468 K - -

All numbers in EUR currency

Indicator range from annual reports

Maximum Minimum Average
-468 K -26.8 M -10.2 M

References

  1. Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer EBITDA Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
-508 M - 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
-88.1 M - 1052.0 % $ 415 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
-143 M $ 18.46 -0.22 % $ 2.72 B usaUSA
Amgen Amgen
AMGN
12.8 B $ 344.63 0.8 % $ 185 B usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
121 M $ 70.06 1.05 % $ 9.37 B usaUSA
I-Mab I-Mab
IMAB
13.8 M - - $ 866 M chinaChina
Biogen Biogen
BIIB
673 M $ 179.46 -0.24 % $ 26.1 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
-2.45 M $ 2.7 3.85 % $ 17 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
3.11 B - - $ 40.3 B usaUSA
Adagene Adagene
ADAG
-35.2 M $ 2.6 -5.45 % $ 146 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
-7 M - -18.52 % $ 27.3 M britainBritain
Burford Capital Limited Burford Capital Limited
BUR
242 M $ 9.78 0.93 % $ 1.57 B britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-8.18 M - -1.52 % $ 24.7 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-285 M - - $ 3.67 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
-17.3 M $ 3.14 -0.95 % $ 7.55 B australiaAustralia
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-10.1 M $ 4.32 7.67 % $ 9.4 B israelIsrael
Acorda Therapeutics Acorda Therapeutics
ACOR
-233 M - -24.86 % $ 820 K usaUSA
Aptose Biosciences Aptose Biosciences
APTO
32 K - -45.71 % $ 1.2 M canadaCanada
Acasti Pharma Acasti Pharma
ACST
-16.7 M - 4.01 % $ 150 M canadaCanada
Compugen Ltd. Compugen Ltd.
CGEN
-34.6 M $ 1.83 -0.3 % $ 164 M israelIsrael
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-242 M - - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
-44.7 M $ 1.41 - $ 264 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
-123 M - -0.23 % $ 916 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
-192 M $ 24.98 1.54 % $ 1.61 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
220 M - - - russiaRussia
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-47.3 M - 3.16 % $ 1.9 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-452 M $ 226.97 0.38 % $ 5 B danmarkDanmark
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
122 K - -11.43 % $ 502 K usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
-131 M $ 3.86 1.72 % $ 116 M franceFrance
Applied Molecular Transport Applied Molecular Transport
AMTI
-124 M - - $ 10.1 M usaUSA
Aravive Aravive
ARAV
-70 M - -13.39 % $ 1.45 M usaUSA
BioNTech SE BioNTech SE
BNTX
15.3 B $ 109.35 -3.87 % $ 27.2 B germanyGermany
Athira Pharma Athira Pharma
ATHA
-99.9 M - - $ 269 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-8.67 M - 5.93 % $ 314 M canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-234 M $ 1.38 0.73 % $ 352 M britainBritain
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
138 M $ 42.1 5.59 % $ 4.35 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
-9.76 M - -10.17 % $ 12.2 K usaUSA
AVROBIO AVROBIO
AVRO
10.8 M - 1083.1 % $ 745 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
196 M $ 24.77 1.93 % $ 2.93 B usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
-48.2 M $ 1.7 -3.14 % $ 81 M usaUSA
Akouos Akouos
AKUS
-84.3 M - 0.23 % $ 488 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
-130 M - -15.15 % $ 60.3 M britainBritain
Brickell Biotech Brickell Biotech
BBI
-6.32 M - -5.38 % $ 6.06 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
312 M $ 13.96 2.01 % $ 4.31 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
-11.4 M - 1.93 % $ 17.4 M usaUSA
Atreca Atreca
BCEL
5.46 M - -11.76 % $ 5.79 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
-412 M - - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
-24.5 M - 2.71 % $ 14 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
-1.3 M $ 6.58 - $ 1.36 B usaUSA